ANTARES PHARMA INC Form 8-K May 03, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) April 28, 2005

ANTARES PHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of 0-20945 (Commission File Number) 41-1350192 (IRS Employer

Incorporation)

Identification No.)

707 Eagleview Boulevard, Suite 414, Exton, PA (Address of Principal Executive Offices) 19341 (Zip Code)

Registrant s telephone number, including area code (610) 458-6200

Edgar Filing: ANTARES PHARMA INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ANTARES PHARMA INC - Form 8-K

Item 7.01. Regulation FD Disclosure.

On April 28, 2005, Antares Pharma, Inc. held its annual meeting. The slides attached as Exhibit 99.1 were presented at the annual meeting.

The information in Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

- (c) Exhibits.
- 99.1 PowerPoint Slides Used at Annual Meeting (furnished)

Edgar Filing: ANTARES PHARMA INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 2, 2005

By /s/ Lawrence M. Christian
Lawrence M. Christian

Its Chief Financial Officer